Glenmark Pharmaceuticals Q1 PAT down 86% dragged by US litigation settlement provision

Consolidated total revenue from operations in Q1FY26 stood at ₹3,264.44 crore as against ₹3,244.19 crore in the same period a year ago.

Read Full Article →